Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus BROVANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus BROVANA.
ASBRON vs BROVANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Category C
Category C
Bronchodilator
Bronchodilator